

AQILION

Helsingborg, March 12, 2025

Press release

THE INFORMATION IN THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD VIOLATE ANY APPLICABLE LAWS OR REGULATIONS.

Aqilion extends period for subscription of ongoing rights rights issue

The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on March 12, 2025, decided to extend the subscription period for the Company's ongoing rights issue until March 26, 2025.

The subscription period now runs until March 26, 2025, instead of March 12, 2025 as previously communicated. The new subscription period thus runs during the period February 26, 2025 until March 26, 2025 and the timetable for the rights issue is adjusted in accordance with the extension. For other terms and conditions regarding the offer, please refer to the press release which Aqilion published as of February 12, 2025 and the information memorandum distributed to shareholders on February 21, 2025.

The Board has assessed that an extended subscription period is to the benefit of the Company and the existing shareholders as it ensures that the Company's foreign shareholders and stakeholders have time to subscribe for shares during the subscription period.

The last day of the subscription period is March 26, 2025, and the estimated date for the announcement of the outcome of the rights issue is April 2, 2025

Counsellors

Redeye AB is acting as financial advisor, HWF Advokater AB is acting as legal advisor and Nordic Issuing AB is acting as issuing agent to Aqilion in connection with the rights issue.

For further information, please contact:

Sarah Fredriksson, vd, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com
Gustaf Albèrt, CFO, AQILION AB, + 46 (0)709 168 302, gustaf.albert@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes its development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Aqilion. Any invitation to the persons concerned to subscribe for shares in Aqilion will only be made through the information memorandum that Aqilion expects to distribute to existing shareholders on 21 February 2025.

The information in this press release may not be announced, published or distributed, directly or indirectly, to any party or country other than Sweden.

Aqilion has made the assessment that the Company conducts activities worthy of protection in accordance with the Act (2023:560) on the Review of Foreign Direct Investments (the "FDI Act"). This means that investors who achieve certain influence in the Company may need to notify investments in the Company to, and obtain approval from, the Swedish Inspectorate for Strategic Products (ISP) before such an investment can be made. Each investor should consult an independent legal advisor on the possible application of the FDI law in connection with the rights issue for the individual investor.